Pre-market Hot Trades in US Stocks

Astera Labs is up 8.96% in pre-market trading. Based on recent key news:

1. On July 29, Astera Labs' momentum indicators weakened, with the MACD below the signal line and negative histogram indicating a decrease in buying momentum. The stock price fell 7.77%, closing at $260.56; if it breaks through the $263 resistance level, the technical outlook may improve.

2. On July 29, the market has high expectations for Astera Labs' earnings report on August 4, and the results may determine whether the stock price correction is a buying opportunity or a trap.

3. On July 30, top analysts believe Astera Labs is not one of the best stocks to buy currently, despite its rating being a moderate buy, as five other stocks are considered more attractive. The market has high expectations for Astera Labs' earnings report, while the technicals are weak.

Bloom Energy is up 8.92% in pre-market trading. Based on recent key news:

1. On July 29, Bloom Energy announced its second-quarter earnings report, with adjusted earnings per share of $0.78, far exceeding analysts' expectations of $0.40, and revenue of $1.07 billion, higher than the expected $838.7 million. The company raised its full-year guidance, expecting annual revenue of $3.9 billion to $4.2 billion, driving the stock price up over 9% in pre-market. Source: Guandian.com

2. On July 29, Bloom Energy announced a power supply agreement with an AI data center, raising its full-year revenue guidance to $3.9 billion to $4.2 billion, with a non-GAAP earnings per share guidance of $2.55 to $2.85. Clear Street analysts upgraded the rating to buy, with a target price of $290. Source: CaiLianShe

3. On July 29, Bloom Energy benefited from a surge in demand for AI infrastructure, reporting a net profit of $196 million in the second quarter, turning from a loss to a profit year-on-year, with the stock price rising 12.68% after hours. Source: Hong Kong Economic Journal. The demand for AI drives significant stock price fluctuations, and risks need to be monitored.

Top Gainers in Pre-market US Stocks

Weibasi is up 227.67% in pre-market trading. Based on recent key news:

1. On July 30, Wetour Robotics announced a 1-for-100 stock consolidation plan. This move aims to increase the stock price and improve market liquidity, expected to take effect on August 3. This news may trigger positive market expectations for the company's future development, driving the stock price up.

2. On July 29, Fermi and Galaxy Digital face challenges amid changes in cryptocurrency regulation, with investors' interest in risk assets fluctuating. Such market conditions may affect the stock performance of related companies On July 29, Sprott Physical Silver Trust, as an indicator of inflation expectations and industrial demand, showed a response to market uncertainty. Such macroeconomic factors may impact stock prices in related industries. Changes in cryptocurrency regulation affect market sentiment.

Onfolio pre-market rose 153.44%. Based on recent key news:

1. On July 28, Onfolio announced it is seeking strategic alternatives to maximize shareholder value. The company plans to evaluate acquisitions, transformation deals, and divestitures of underperforming assets, focusing resources on core business. This news significantly boosted the stock price. Source: Reuters

2. On July 29, Onfolio's trading volume surged to approximately 212 million shares, while the three-month average daily trading volume was only about 1.08 million shares. The active trading indicates high market attention to the company's strategic adjustments. Source: TipRanks

3. On July 29, TipRanks' AI analyst Spark rated Onfolio stock as underperforming, with a target price of $0.09, citing weak financial performance and bearish technicals. The analyst's negative assessment may pressure the stock price. Source: TipRanks The U.S. stock market has recently experienced increased volatility, and risks should be monitored.

Replimune pre-market rose 111.28%. Based on recent key news:

1. On July 28, U.S. FDA reviewers expressed concerns about Replimune's RP1 drug trial, stating that the trial data was insufficient to demonstrate its efficacy, leading to a pre-market drop of 21% in stock price.

2. On July 30, the FDA advisory committee's review of the RP1 drug yielded positive results, with experts voting in support of the trial results, driving the stock price up in pre-market.

3. On July 31, Replimune announced that the FDA advisory committee meeting results were favorable, and it expects to resubmit the Biologics License Application for RP1 on August 2, further boosting the stock price. The FDA review results have driven stock price volatility, and regulatory risks in the industry remain